Carcinoembryonic antigen (NYSE:CEA) is a protein produced when the fetus is developing but is absent in adults. However, the presence of CEA in abnormal amounts can lead to cancer. A CEA test is conducted to measure the level of proteins and keep a check on the recurrence of colon or other types of cancers in patients who are already diagnosed with cancer. The accepted range of this protein is between 0 and 0.25 micro-organisms per liter. Presence of CEA at an elevated level in recently treated cancer patients indicates recurrence of the ailment.
Transparency Market Research, in a new report, titled "CEA Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," provides a comprehensive overview of the global market for CEA testing. It studies the market from the ground up, covering aspects such as the market's definition, segmentation based on various parameters, and factors impacting its growth over the forecast period from 2013 to 2019.
The elevated levels of CEA are attributed to various types of cancers and other conditions such as heavy smoking, lung infection, cholecystitis, peptic ulcer, and inflammatory bowel disease. Additionally, hematoma, which occurs when blood accumulates under the skin, dizziness, infection, and excessive bleeding are other risks commonly associated with the presence of CEA in abnormal levels. It is possible to diagnose the level of CEA in body by using arcitumomab, which is a monoclonal antibody. Arcitumomab is also used to identify glycoprotein expression in tissue samples.
Request for Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1628
In the last few years, the global market for CEA testing has exhibited impressive growth, due to the evolution of the latest technologies and the discovery of specific biomarkers and antigens. Additionally, the rising incidence of cancer and other chronic ailments has been aiding the expansion of the market as well. To provide a holistic overview, the report segments the market on the basis of instrumentation in terms of tests performed in specific regions. The future prospects of the CEA testing market have been measured by conducting a qualitative analysis on patent protection and the regulatory policies prevalent in the market.
Substantially benefitted by technological breakthroughs in genetic analysis of the disease and accuracy of diagnosis, and rigorous research and development activities, the global CEA testing market is anticipated to exhibit a positive CAGR during the report's forecast period. The market will also gain impetus from the growing geriatric population and the subsequent rise in chronic ailments worldwide.
Despite witnessing positive growth prospects, the market's trajectory will be inhibited due to the inadequate awareness regarding the novel technologies available in the CEA testing market. To study the market from a bird's eye view, the report also profiles some of the leading companies operating therein such as Danaher Corporation (Beckman Coulter), Abbott Laboratories, Epigenomics, Life Technologies Corporation, Siemens Healthcare, BioMerieux, Qiagen N.V., and, Myriad Genetics.
The exhaustive information and relevant statistic compiled in the report are intended to update stakeholders about the prevalent market dynamics and assist them in determining winning strategies for the future.
Mr. Sudip S
Transparency Market Research
90 State Street,
NY - 12207
USA - Canada Toll Free 866-552-3453